| Phase 4 |
| NCT05525767 |
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer |
Solid Tumor |
Recruiting |
2025-12-11 |
| NCT06217185 |
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment… |
HER2-positive Breast Cancer |
Recruiting |
2024-02-28 |
| NCT07668570 |
SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma |
HCC - Hepatocellular Carcinoma |
Not Yet Recruiting |
2026-06-25 |
| NCT07004335 |
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With… |
PD-(L)1 |
Not Yet Recruiting |
2025-06-04 |
| Phase 2/3 |
| NCT07585279 |
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal… |
Metastatic Colorectal Cancer (CRC) |
Not Yet Recruiting |
2026-05-13 |
| NCT04290793 |
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by… |
Breast Cancer |
Active, Not Recruiting |
2026-01-07 |
| Phase 2 |
| NCT07744932 |
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma |
Oligometastatic Clear Cell Renal Cell Carcinoma |
Recruiting |
2026-08-04 |
| NCT06949098 |
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low… |
Rectal Cancer Stage I |
Recruiting |
2026-08-03 |
| NCT06949111 |
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon… |
Colon Cancer |
Recruiting |
2026-08-03 |
| NCT07179900 |
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic… |
Hepatocellular Carcinoma |
Recruiting |
2026-08-03 |
| NCT07448077 |
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC |
Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer |
Recruiting |
2026-07-31 |
| NCT06435260 |
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for… |
Pancreatic Cancer |
Recruiting |
2026-07-06 |
| NCT07635342 |
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer |
HER2-positive Breast Cancer |
Recruiting |
2026-06-09 |
| NCT07492394 |
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer |
Breast Cancer |
Recruiting |
2026-04-02 |
| NCT07289997 |
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the… |
AFP Gastric or Gastroesophageal Junction Adenocarcinoma |
Recruiting |
2025-12-17 |
| NCT07290010 |
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With… |
Esophageal Squamous Cell Carcinoma (ESCC) |
Recruiting |
2025-12-17 |
| NCT06107673 |
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant… |
Breast Cancer |
Recruiting |
2025-12-11 |
| NCT07266480 |
Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell… |
Squamous Oesophageal Cancer |
Recruiting |
2025-12-05 |
| NCT04138719 |
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant… |
Breast Cancer |
Recruiting |
2025-09-11 |
| NCT04159142 |
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment… |
Triple Negative Breast Cancer |
Recruiting |
2025-09-11 |
| NCT06646588 |
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal… |
Esophageal Neoplasms |
Recruiting |
2024-10-17 |
| NCT06184698 |
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic… |
Colorectal Cancer |
Recruiting |
2024-10-09 |
| NCT06371482 |
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer… |
SCLC, Limited Stage |
Recruiting |
2024-06-17 |
| NCT03964753 |
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal… |
Esophageal Squamous Cell Carcinoma |
Recruiting |
2023-10-10 |
| NCT05241028 |
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer |
Non-small Cell Lung Cancer |
Recruiting |
2023-10-10 |